Aims & Scope

The British Journal of Dermatology (BJD) strives to publish the highest quality dermatological research. In so doing, the journal aims to advance understanding, management and treatment of skin disease and improve patient outcomes.

BJD invites submissions under a broad scope of topics relevant to clinical and experimental research and publishes original articles, reviews, concise communications, case reports and items of correspondence. The article categories within the journal are: cutaneous biology; clinical and laboratory investigations; contact dermatitis & allergy; dermatological surgery & lasers; dermatopathology; epidemiology & health services research; paediatric dermatology; photobiology; and therapeutics.

BJD is an official organ of the British Association of Dermatologists but attracts contributions from all countries in which sound research is carried out, and its circulation is equally international. The overriding criteria for publication are scientific merit, originality and interest to a multidisciplinary audience.

Journal content and further information - including author guidelines and submission details - can be found online at www.brjdermatol.org. The 2010 impact factor is 4.353.

Mission & Values

Founded in 1888, BJD has evolved into one of the world's leading general dermatology journals. The BJD brand is underpinned by the provision of trusted information. From this solid foundation, the journal aims to serve the needs of its multiple stakeholders.

• For authors, BJD aims to provide a quick, dependable and fair peer-review service focused on improving the quality of accepted manuscripts. Article production should be quick and accurate and free of any charges.
• BJD recognises the invaluable role of reviewers in safeguarding the integrity of content and aims to acknowledge fully their contribution.
• For readers, BJD aims to deliver the highest quality clinical and experimental research spanning the continuum of dermatological disciplines. Content should be readily discoverable and user-friendly. Online innovation should add value to content, promote understanding and facilitate clinical decision-making.
• For subscribers, BJD aims to offer flexible purchasing options - from individual article downloads to multi-year, multi-site licences - at reasonable prices.
• For sponsors, BJD aims to offer ethical marketing solutions which yield measurable returns on investment.

Product Detail

First choice in dermatology

• One of the top dermatology journals in the world: 2010 Impact Factor - 4.353
• High quality original research of instant importance: 2010 Immediacy Index - 0.821

Speed of Publication

• Rapid, robust peer review - average 15 days from submission to first decision
• Immediate preprint publication upon article acceptance
• 70 days from receipt at publisher to print publication
• No page or colour charges
• Fully compliant with NIH Public Access Policy

International Readership

• Available in more than 8,000 medical and scientific libraries worldwide
• 80,000 page views per month
• Free e-alerts or RSS feeds for all registered users
• OnlineOpen: articles 'open access' upon payment of a one time author fee

Join the ranks of the world's best authors and submit your next paper to BJD

TopNews and Announcements

Latest News

Plant sap may provide cure for skin cancer

Read the press release

Access the article

TopHighlights

Top 10 Most Cited Articles from 2008*

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J.-H. Saurat, G. Stingl, L. Dubertret, et al.
Volume: 158 Issue: 3 Pages: 558-566 Published: MAR 2008

Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis
J.L. Abraham, C. Thakral, L. Skov, et al.
Volume: 158 Issue: 2 Pages: 273-280 Published: FEB 2008

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis
C. Leonardi, A. Menter, T. Hamilton, et al.
Volume: 158 Issue: 5 Pages: 1107-1116 Published: MAY 2008

Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways
K.E. Nograles, L.C. Zaba, E. Guttman-Yassky, et al.
Volume: 159 Issue: 5 Pages: 1092-1102 Published: NOV 2008

Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
T. Ruzicka, C.W. Lynde, G.B.E. Jemec, et al.
Volume: 158 Issue: 4 Pages: 808-817 Published: APR 2008

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy
C-H. Yang, W-C. Lin, C-K. Chuang, et al.
Volume: 158 Issue: 3 Pages: 592-596 Published: MAR 2008

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis
D. Revicki, M.K. Willian, J.-H. Saurat, et al.
Volume: 158 Issue: 3 Pages: 549-557 Published: MAR 2008

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials
A.K. Brimhall, L.N. King, J.C. Licciardone, et al.
Volume: 159 Issue: 2 Pages: 274-285 Published: AUG 2008

Guidelines for topical photodynamic therapy: update
C.A. Morton, K.E. McKenna, L.E. Rhodes
Volume: 159 Issue: 6 Pages: 1245-1266 Published: DEC 2008

Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis
J.A. Kaye, L. Li, S.S. Jick
Volume: 159 Issue: 4 Pages: 895-902 Published: OCT 2008

*As per 15th April 2010